May 6, 2015

LifeVantage Announces Third Quarter Fiscal Year 2015 Results

Revenue During First Nine Months of Fiscal Year 2015 in the Americas Increased 2.8%

Repurchased $9.9 Million of Common Stock in First Nine Months of Fiscal Year 2015

 Reduced Long-Term Debt by $3.5 Million in First Nine Months of Fiscal Year 2015

Reaffirms Fiscal Year 2015 Outlook Range


SALT LAKE CITY, May 6, 2015 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) today reported financial results for its third quarter and nine months ended March 31, 2015.

Third Quarter Fiscal 2015 Highlights:

  • Revenue was $45 million compared to $55 million in the prior year period;
  • Revenue in the Americas increased by 1% compared to the prior year period;
  • Adjusted EBITDA was $3.3 million, compared to $5.7 million in the prior year period;
  • Identified annual cost structure savings of approximately $4 million.

Dave S. Manovich, Executive Vice Chairman of LifeVantage stated, "We are very pleased with our recently announced appointment of Darren Jensen as our next President and Chief Executive Officer. Throughout the transition to a new CEO, we have focused on taking the necessary steps to help us reignite top and bottom line growth. We have identified approximately $4 million in annual cost reductions.  Approximately $1.3 million has already been implemented through headcount reductions and the remaining $2.7 million will be implemented in selling, general and administrative expense reductions over the course of fiscal 2016.  Upon joining the company in mid-May, Mr. Jensen will have the flexibility to further shape, drive and articulate the Company's strategic initiatives." 

Mr. Manovich continued, "While our year-to-date revenue in the Americas grew approximately 3% compared to the prior year, our Asia Pacific revenue declined 28%.   We are not pleased with these current revenue trends and remain committed to improving the level of engagement with our strong distributor base and expanding awareness and understanding of our full product lineup."

Third Quarter Fiscal 2015 Results

For the third fiscal quarter ended March 31, 2015, the Company reported revenue of $45.2 million, compared to $55.1 million for the same period in fiscal 2014. Revenue includes an increase of 1% in the Americas, and a decrease in the Asia/Pacific region of 45%. The year-over-year decline in the Asia/Pacific region is primarily due to Japan's lower volume, negative foreign currency exchange and a benefit in the prior year period from customers accelerating purchasing in advance of announced price increases that went into effect on April 1, 2014. Revenue for the quarter was negatively impacted $1.8 million, or 3%, by foreign currency fluctuation.

Commissions and incentives for the third fiscal quarter of 2015 were $21.6 million, or 47.9% of revenue, compared to $26.8 million, or 48.6% of revenue, in the same period last year. Selling, general and administrative expenses (SG&A) for the third fiscal quarter of 2015 were $14.5 million, or 32.1% of revenue, compared to $15.4 million, or 27.9% of revenue, in the same period last year. SG&A expenses in the third fiscal quarter of 2015 include $1.2 million in one-time expenses, including CEO severance costs, the engagement of an executive search firm and one-time investments in new sales events.

Operating income for the third fiscal quarter of 2015 was $1.5 million, compared to $4.5 million in the third fiscal quarter of 2014. 

Net income for the third fiscal quarter of 2015 was $0.6 million, or $0.01 per diluted share, calculated on 97.7 million fully diluted shares.  This compares to net income in the third fiscal quarter of 2014 of $2.5 million, or $0.02 per diluted share, calculated on 106.6 million fully diluted shares.  Adjusted EBITDA was $3.3 million for the third fiscal quarter of 2015, compared to $5.7 million in the prior year period. Adjusted EBITDA excludes the CEO severance and related executive search firm expenses. 

Fiscal 2015 First Nine Months Results

For the nine months ended March 31, 2015, the Company reported net revenue of $145.0 million, compared to $157.9 million in the prior year period. Revenue in the Americas increased 3%, while revenue in the Asia/Pacific region decreased 28% due primarily to lower sales in Japan. Revenue for the first nine months of fiscal 2015 was negatively impacted $4.0 million, or 7%, by foreign currency fluctuation.

Operating income for the first nine months of fiscal 2015 was $12.3 million, compared to $14.7 million in the prior year period.

Net income for the first nine months of fiscal 2015 was $6.8 million, or $0.07 per diluted share, compared to $9.0 million, or $0.08 per diluted share in the prior year period. Additionally, Adjusted EBITDA was $14.3 million for the first nine months of fiscal 2015, compared to $18.4 million in the prior year period. 

Balance Sheet & Liquidity

The Company generated $9.0 million of cash flow from operations in the first nine months of fiscal 2015.  Cash flow benefited from a one-time cash settlement of approximately $2 million in the first quarter. The Company's cash and cash equivalents at March 31, 2015 were $15.4 million, compared to $20.4 million at the end of fiscal year 2014. The Company repaid $3.5 million of debt during the first nine months of fiscal 2015. In addition, during the first nine months of fiscal 2015 the Company has returned $9.9 million to shareholders by repurchasing a total of 7.6 million shares. Inventory increased $2.0 million compared to June 30, 2014, which is related to the Company's recent product launches, TrueScience and Axio, as well as the recent decline in revenue. On a sequential basis, inventory decreased $1.2 million highlighting the Company's inventory control efforts.     

Fiscal Year 2015 Guidance

The Company is reaffirming its guidance for fiscal year 2015. The Company expects to generate revenue in the range of $185 million to $195 million in fiscal year 2015.  The Company has modeled Japan to decline by approximately 35% with the remaining countries collectively impacting revenue from a negative 3.0% at the bottom end of our range, to a positive 2% at the top end of our range, on a year-over-year basis. The Company expects its operating margin to be in the range of 7% to 9% and earnings per diluted share in the range of $0.07 to $0.08, based on an estimated 100 million diluted shares and a 33% effective tax rate. 

Conference Call Information 

The Company will hold an investor conference call today at 2:30 p.m. Mountain time (4:30 p.m. Eastern time). Investors interested in participating in the live call can dial (888) 256-9128 from the U.S. International callers can dial (913) 312-1430. A telephone replay will be available approximately two hours after the call concludes and will be available through Friday, May 8, 2015, by dialing (877) 870-5176 from the U.S. and entering confirmation code 9503189, or (858) 384-5517 from international locations, and entering confirmation code 9503189.
There also will be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at http://investor.lifevantage.com/events.cfm. The webcast will be archived for approximately 30 days.

About LifeVantage Corporation 

LifeVantage Corporation (Nasdaq:LFVN), is a science based network marketing company that is dedicated to visionary science that looks to transform health, wellness and anti-aging internally and externally at the cellular level. The company is the maker of Protandim®, the Nrf2 Synergizer® patented dietary supplement, the TrueScience Anti-Aging Skin Care Regimen, Canine Health, and the AXIO energy product line. LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah.

Forward Looking Statements

This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to" and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements we make regarding our future revenue, operating income, operating margins, earnings per share, cash flow from operations, our expansion and investment in new and existing international markets, our future results of operations in Japan and future investment and growth. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

About Non-GAAP Financial Measures

We define Non-GAAP EBITDA as earnings before interest expense, income taxes, depreciation and amortization and Non-GAAP Adjusted EBITDA as earnings before interest expense, income taxes, depreciation and amortization, stock compensation expense and other income, net. Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies.

We are presenting Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA because management believes that they provide additional ways to view our operations when considered with both our GAAP results and the reconciliation to net income, which we believe provides a more complete understanding of our business than could be obtained absent this disclosure.  Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA are presented solely as a supplemental disclosure because: (i) we believe it is a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing shareholder value; and (iii) we use Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA internally as a benchmark to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA has limitations and you should not consider these measures in isolation from or as an alternative to the relevant GAAP measure of net income prepared in accordance with GAAP, or as a measure of profitability or liquidity.

The tables set forth below present Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA which are non-GAAP financial measures to Net Income, our most directly comparable financial measure presented in accordance with GAAP.

LIFEVANTAGE CORPORATION AND SUBSIDIARIES 
CONSOLIDATED BALANCE SHEETS 
(Unaudited) 
      
(In thousands, except per share data)As of 
ASSETSMarch  31, 2015 June 30, 2014 
  Current assets    
 Cash and cash equivalents$  15,353  $  20,387  
 Accounts receivable 1,258   1,317  
 Income tax receivable 3,490   4,681  
 Inventory 10,899   8,826  
 Current deferred income tax asset 158   158  
 Prepaid expenses and deposits 3,699   4,604  
   Total current assets 34,857   39,973  
      
 Property and equipment, net 6,239   6,941  
 Intangible assets, net 1,913   2,014  
 Deferred debt offering costs, net 1,164   1,353  
 Long-term deferred income tax asset 1,285   1,285  
 Other long-term assets 1,468   2,433  
TOTAL ASSETS$  46,926  $  53,999  
LIABILITIES AND STOCKHOLDERS' EQUITY     
  Current liabilities    
 Accounts payable$  2,723  $  2,854  
 Commissions payable 6,719   7,594  
 Other accrued expenses 6,154    7,554  
 Current portion of long-term debt 9,200   4,700  
   Total current liabilities 24,796   22,702  
      
Long-term debt    
 Principal amount 18,100   26,125  
 Less: unamortized discount   (905)    (1,052) 
 Long-term debt, net of unamortized discount 17,195   25,073  
   Other long-term liabilities 2,105   2,234  
   Total liabilities 44,096   50,009  
Commitments and contingencies - Note 6    
Stockholders' equity     
 Preferred stock - par value $.001 per share,  50,000 shares authorized; no shares issued or outstanding   -      -   
 Common stock - par value $.001 per share, 250,000 shares authorized and 96,985 and 102,173 issued and outstanding as of March 31, 2015 and June 30, 2014, respectively 97   102  
 Additional paid-in capital 117,248   115,244  
 Accumulated deficit  (114,321)   (111,240) 
 Accumulated other comprehensive loss   (194)    (116) 
   Total stockholders' equity  2,830   3,990  
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$  46,926  $  53,999  
      

 

LIFEVANTAGE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(Unaudited)
        
 For the Three Months Ended
March 31,
 For the Nine Months Ended
March 31,
  2015   2014   2015   2014 
(In thousands, except per share data)        
Revenue, net$  45,155  $  55,064  $  145,035  $  157,930 
Cost of sales   7,552     8,459     20,717     24,212 
Gross profit 37,603   46,605   124,318   133,718 
        
Operating expenses:       
Commissions and incentives 21,637   26,760   69,406   77,558 
Selling, general and administrative  14,481   15,378   42,572   41,457 
Total operating expenses 36,118   42,138   111,978   119,015 
Operating income    1,485     4,467     12,340     14,703 
        
Other income (expense):       
Interest expense   (748)    (1,160)    (2,341)    (1,996)
Other income (expense), net   (13)    (118)    (56)    391 
Total other income (expense)   (761)    (1,278)    (2,397)    (1,605)
Income before income taxes   724     3,189     9,943     13,098 
Income tax expense   (151)    (695)    (3,182)    (4,066)
Net income$  573  $  2,494  $  6,761  $  9,032 
Net income per share:       
Basic$  0.01  $  0.02  $  0.07  $  0.08 
Diluted$  0.01  $  0.02  $  0.07   $  0.08 
Weighted average shares outstanding:       
Basic 96,069   101,594   97,785   107,385 
Diluted 97,725   106,578   99,793   113,717 
        
Other comprehensive income (loss), net of tax:       
Foreign currency translation adjustment   1     103     (78)    (363)
Other comprehensive income (loss), net of tax$  1  $  103  $  (78) $  (363)
Comprehensive income $  574  $  2,597  $  6,683  $  8,669 
        

 

LIFEVANTAGE CORPORATION AND SUBSIDIARIES 
Revenue by Region 
(Unaudited) 
                   
  For the Three Months Ended
March 31,
  For the Nine Months ended
March 31,
 
   2015   2014    2015   2014  
(In thousands)                  
Americas $  32,901   73% $  32,641   59%  $  104,397   72% $  101,557    64% 
Asia/Pacific    12,254   27%    22,423   41%      40,638   28%    56,373   36% 
Total $  45,155   100% $  55,064   100%  $  145,035   100% $  157,930   100% 
                   
  Active Independent Distributors (1)          
  (Unaudited)          
                   
  March 31           
   2015   2014           
Americas  44,000   67%  43,000   59%          
Asia/Pacific  22,000   33%  30,000   41%          
Total  66,000   100%   73,000   100%          
                   
  Active Preferred Customers (2)          
  (Unaudited)          
                   
  March 31          
   2015   2014           
Americas  93,000   82%  106,000   79%          
Asia/Pacific  21,000   18%  28,000   21%          
Total  114,000   100%  134,000   100%          
                   
(1)  Active Independent Distributors have purchased product in the prior three months for retail or personal consumption.   
(2)  Active Preferred Customers have purchased product in the prior three months for personal consumption only.   

 

LIFEVANTAGE CORPORATION AND SUBSIDIARIES 
Reconciliation of GAAP Net Income to Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA 
      
 For the Three Months Ended
March 31,
 For the Nine Months Ended
March 31,
 
  2015   2014    2015   2014  
(In thousands)         
GAAP Net income$  573  $  2,494  $  6,761  $  9,032  
Interest Expense   748     1,160     2,341     1,996  
Provision for income taxes   151      695     3,182     4,066  
Depreciation and amortization   573     530      1,738     1,527  
Non-GAAP EBITDA:    2,045     4,879     14,022     16,621  
Adjustments:        
Stock compensation expense   536     694     1,505      2,169  
Other (income) expense, net   13     118     56     (391) 
Other adjustments*   717     -      (1,283)    -   
Total adjustments   1,266     812     278     1,778  
Non-GAAP Adjusted EBITDA$  3,311  $  5,691  $  14,300  $  18,399  
      
*Total adjustments for the three months ended March 31, 2015 include approximately $0.6 million for CEO severance expenses and $0.2 million for search firm expenses associated with search for a new CEO.  Total adjustments for the nine months ended March 31, 2015 include $0.6 million for CEO severance expenses and $0.2 million for search firm expenses associated with search for a new CEO along with a $2.0 million reduction for a one-time pretax benefit from settlement proceeds. 
         


Investor Relations Contact:

Cindy England (801) 432-9036

Director of Investor Relations

-or-

John Mills (646) 277-1254

Partner, ICR INC

Primary Logo

Source: LifeVantage Corporation

News Provided by Acquire Media


Close window | Back to top

Copyright 2017 LifeVantage Corp.